Giangrande P - Search Results

1

Long-term safety and efficacy of N8-GP in previously treated adults and adolescents with hemophilia A: Final results from pathfinder2.

Giangrande P, Abdul Karim F, Nemes L, You CW, Landorph A, Geybels MS, Curry N. Giangrande P, et al. J Thromb Haemost. 2020 Sep;18 Suppl 1(Suppl 1):5-14. doi: 10.1111/jth.14959. J Thromb Haemost. 2020. PMID: 32544297 Free PMC article. Clinical Trial.

2

Clinical evaluation of glycoPEGylated recombinant FVIII: Efficacy and safety in severe haemophilia A.

Giangrande P, Andreeva T, Chowdary P, Ehrenforth S, Hanabusa H, Leebeek FW, Lentz SR, Nemes L, Poulsen LH, Santagostino E, You CW, Clausen WH, Jönsson PG, Oldenburg J; Pathfinder™2 Investigators. Giangrande P, et al. Thromb Haemost. 2017 Jan 26;117(2):252-261. doi: 10.1160/TH16-06-0444. Epub 2016 Dec 1. Thromb Haemost. 2017. PMID: 27904904 Clinical Trial.

3

Achievement of immune tolerance in a patient with haemophilia B and inhibitory antibodies, complicated by an anaphylactoid reaction.

Curry NS, Misbah SA, Giangrande PL, Keeling DM. Curry NS, et al. Among authors: giangrande pl. Haemophilia. 2007 May;13(3):328-30. doi: 10.1111/j.1365-2516.2007.01463.x. Haemophilia. 2007. PMID: 17498084

4

Recombinant factor VIIa analog in the management of hemophilia with inhibitors: results from a multicenter, randomized, controlled trial of vatreptacog alfa.

Lentz SR, Ehrenforth S, Karim FA, Matsushita T, Weldingh KN, Windyga J, Mahlangu JN; adept™2 investigators. Lentz SR, et al. J Thromb Haemost. 2014 Aug;12(8):1244-53. doi: 10.1111/jth.12634. Epub 2014 Jul 16. J Thromb Haemost. 2014. PMID: 24931322 Free PMC article. Clinical Trial.

5

Clinical evaluation of bleeds and response to haemostatic treatment in patients with acquired haemophilia: A global expert consensus statement.

Tiede A, Giangrande P, Teitel J, Amano K, Benson G, Nemes L, Jiménez-Yuste V, d'Oiron R, Benchikh El Fegoun S, Kessler CM. Tiede A, et al. Among authors: giangrande p. Haemophilia. 2019 Nov;25(6):969-978. doi: 10.1111/hae.13844. Epub 2019 Sep 13. Haemophilia. 2019. PMID: 31517435

6

40K glycoPEGylated, recombinant FVIIa: 3-month, double-blind, randomized trial of safety, pharmacokinetics and preliminary efficacy in hemophilia patients with inhibitors.

Ljung R, Karim FA, Saxena K, Suzuki T, Arkhammar P, Rosholm A, Giangrande P; Pioneer™1 Investigators. Ljung R, et al. Among authors: giangrande p. J Thromb Haemost. 2013 Jul;11(7):1260-8. doi: 10.1111/jth.12237. J Thromb Haemost. 2013. PMID: 23578227 Free article. Clinical Trial.

7

Gene therapy for hemophilia? No.

Giangrande PL. Giangrande PL. J Thromb Haemost. 2004 Aug;2(8):1236-7. doi: 10.1111/j.1538-7836.2004.00869.x. J Thromb Haemost. 2004. PMID: 15304021 Free article. No abstract available.

8

Treatment of hemophilia: recombinant factors only? Yes.

Giangrande PL. Giangrande PL. J Thromb Haemost. 2003 Feb;1(2):214-5. doi: 10.1046/j.1538-7836.2003.00049.x. J Thromb Haemost. 2003. PMID: 12871489 Free article. No abstract available.

9

Adverse effects of treatment with porcine factor VIII.

Gringeri A, Santagostino E, Tradati F, Giangrande PL, Mannucci PM. Gringeri A, et al. Among authors: giangrande pl. Thromb Haemost. 1991 Mar 4;65(3):245-7. Thromb Haemost. 1991. PMID: 1904652

10

The incidence of factor VIII and factor IX inhibitors in the hemophilia population of the UK and their effect on subsequent mortality, 1977-99.

Darby SC, Keeling DM, Spooner RJ, Wan Kan S, Giangrande PL, Collins PW, Hill FG, Hay CR; UK Haemophilia Centre Doctors' Organisation. Darby SC, et al. Among authors: giangrande pl. J Thromb Haemost. 2004 Jul;2(7):1047-54. doi: 10.1046/j.1538-7836.2004.00710.x. J Thromb Haemost. 2004. PMID: 15219185 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

207 results

Search Page